Center for Clinical & Translational ResearchJulianna2022-05-31T14:31:28-04:00
The clinical and translational research community at MHIR is a closely-linked, multi-disciplinary scientific enterprise in which basic, clinical and translational researchers plan and conduct studies as collaborators and scientific colleagues. With the tripod of research, education and patient care as the center of our endeavor, we are forging the interdisciplinary divide between clinical, translational, and basic research.
We provide the opportunity and environment for translational research to flourish through mentorship opportunities, research navigation, and regulatory assistance. We have established core facilities to enhance and facilitate translational research being performed by an assembled group of basic and clinical researchers at MHIR.
Dr. David Seder is the Principal Investigator of an international, multi-site clinical trial to improve outcomes for patients who have suffered a severe stroke by assessing best timing of tracheostomys. This research is awarded by the Patient Centered Outcomes Research Institute (PCORI). See www.setpoint2.org to learn more about this study.
Dr. Irwin Brodsky is the Principal Investigator of D2d Maine Study. D2d (vitamin D and type 2 diabetes) study is a large clinical trial taking place in more than 20 cities across the United States. The study is funded by the National Institutes of Health and the American Diabetes Association. The goals of the D2d study are to find out if vitamin D supplementation is safe and effective in delaying the development of type 2 diabetes in people at risk for the disease and to better understand how vitamin D affects the body’s ability to use glucose (sugar).
MMC’s Cystic Fibrosis Research Program directed by Dr. Ana Cairns (Pediatrics) and Dr. Jonathan Zuckerman (Adult) currently has 10 active clinical trials, which comprise a blend of industry, federal, and foundation-funded studies. The mission of the research is to further our understanding of cystic fibrosis and develop therapies to improve outcomes for CF patients. The program has a strong infrastructure supported through participation in a nationwide clinical trials network (Cystic Fibrosis Foundation Therapeutic Development Network).The program has since extended the scope of inquiry to include a number of investigator initiated projects. Recent studies have explored use of probiotics, biomarkers of lung disease, and best practices for outpatient infection control and venous catheter management in the CF population.